

Emmanuelle Bompas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9295253/publications.pdf>

Version: 2024-02-01

98
papers

7,521
citations

61687

45
h-index

62345

84
g-index

101
all docs

101
docs citations

101
times ranked

8063
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group. <i>International Journal of Cancer</i> , 2022, 150, 645-653.	2.3	9
2	Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG). <i>ESMO Open</i> , 2022, 7, 100402.	2.0	8
3	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. <i>Nature Medicine</i> , 2022, 28, 1199-1206.	15.2	88
4	No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networksâ€™ Outcome?. <i>Cancers</i> , 2022, 14, 2620.	1.7	4
5	Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan. <i>Cancer</i> , 2022, 128, 3360-3369.	2.0	2
6	Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. <i>Bulletin Du Cancer</i> , 2021, 108, 163-176.	0.6	7
7	Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC) Tj ETQq1 1 0,784314 rgeBT /Over 463-475.	5.1	95
8	Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?. <i>Cancers</i> , 2021, 13, 1683.	1.7	11
9	Determinants of the access to remote specialised services provided by national sarcoma reference centres. <i>BMC Cancer</i> , 2021, 21, 631.	1.1	14
10	A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. <i>Annals of Oncology</i> , 2021, 32, 1034-1044.	0.6	24
11	A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery. <i>ESMO Open</i> , 2021, 6, 100209.	2.0	17
12	Rare bone sarcomas: a retrospective analysis of 145 adult patients from the French Sarcoma Group. <i>International Journal of Cancer</i> , 2021, , .	2.3	0
13	Results of APIâ€™AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcomeâ€™09 study. <i>International Journal of Cancer</i> , 2020, 146, 413-423.	2.3	18
14	A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study). <i>European Journal of Cancer</i> , 2020, 125, 31-37.	1.3	23
15	Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapyâ€™A Multicenter Study by the French Sarcoma Group. <i>American Journal of Roentgenology</i> , 2020, 215, 1539-1548.	1.0	21
16	Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma. <i>Cancers</i> , 2020, 12, 3647.	1.7	3
17	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 446-455.	5.1	182
18	Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA). <i>BMC Cancer</i> , 2020, 20, 117.	1.1	12

#	ARTICLE	IF	CITATIONS
19	A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. <i>European Journal of Cancer</i> , 2020, 126, 45-55.	1.3	9
20	Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 1818-1827.	0.7	28
21	A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1633-1637.	1.2	4
22	Pazopanib or methotrexate+vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1263-1272.	5.1	123
23	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. <i>Scientific Reports</i> , 2019, 9, 14551.	1.6	41
24	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. <i>European Journal of Cancer</i> , 2019, 119, 151-157.	1.3	103
25	Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients. <i>Surgical Oncology</i> , 2019, 29, 107-112.	0.8	46
26	Surgery in reference centers improves survival of sarcoma patients: a nationwide study. <i>Annals of Oncology</i> , 2019, 30, 1143-1153.	0.6	191
27	Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. <i>Clinical Cancer Research</i> , 2019, 25, 4611-4615.	3.2	13
28	Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years. <i>International Journal of Cancer</i> , 2019, 145, 2135-2143.	2.3	10
29	Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas. <i>JAMA Oncology</i> , 2018, 4, 93.	3.4	303
30	Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. <i>European Journal of Cancer</i> , 2018, 88, 57-66.	1.3	74
31	Can we cure patients with abdominal desmoplastic small round cell tumor? Results of a retrospective multicentric study on 100 patients. <i>Annals of Oncology</i> , 2018, 29, viii579.	0.6	0
32	Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: A French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study. <i>Annals of Oncology</i> , 2018, 29, viii753.	0.6	9
33	Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , 2018, 23, 948-955.	1.9	18
34	Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017. <i>Annals of Oncology</i> , 2018, 29, viii576.	0.6	7
35	Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial. <i>BMC Cancer</i> , 2018, 18, 963.	1.1	15
36	Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 399-406.	0.4	27

#	ARTICLE	IF	CITATIONS
37	Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study. <i>Cancer Medicine</i> , 2018, 7, 4023-4035.	1.3	39
38	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2018, 99, 28-36.	1.3	13
39	Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11508-11508.	0.8	5
40	Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). <i>European Journal of Cancer</i> , 2017, 79, 119-128.	1.3	45
41	Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG). <i>European Journal of Surgical Oncology</i> , 2017, 43, 1110-1116.	0.5	10
42	Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. <i>European Journal of Cancer</i> , 2017, 83, 125-131.	1.3	134
43	Comment je raisonne devant une masse rotropritonale. <i>Medecine Nucleaire</i> , 2017, 41, 280-290.	0.2	0
44	Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTCMs). <i>Clinical Sarcoma Research</i> , 2017, 7, 10.	2.3	15
45	A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. <i>Scientific Reports</i> , 2017, 7, 17917.	1.6	10
46	Improved survival using specialized multidisciplinary board in sarcoma patients. <i>Annals of Oncology</i> , 2017, 28, 2852-2859.	0.6	255
47	Initial FDG-PET/CT predicts survival in adults Ewing sarcoma family of tumors. <i>Oncotarget</i> , 2017, 8, 77050-77060.	0.8	13
48	Circulating vascular endothelial growth factor (VEGF) as prognostic factor of progression-free survival in patients with advanced chordoma receiving sorafenib: An analysis from a phase II trial of the French Sarcoma Group (GSF/GETO). <i>Annals of Oncology</i> , 2016, 27, vi486.	0.6	1
49	Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 632-641.	5.1	98
50	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1732-1742.	5.1	200
51	The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment. <i>Annals of Oncology</i> , 2016, 27, vi483.	0.6	7
52	Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS). <i>Annals of Oncology</i> , 2016, 27, vi483.	0.6	4
53	A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high grade undifferentiated uterine sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment. <i>Annals of Oncology</i> , 2016, 27, vi492.	0.6	0
54	Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1070-1080.	5.1	170

#	ARTICLE	IF	CITATIONS
55	Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). <i>European Journal of Cancer</i> , 2016, 56, 77-84.	1.3	113
56	Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. <i>European Journal of Cancer</i> , 2016, 57, 31-38.	1.3	71
57	Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). <i>Oncotarget</i> , 2016, 7, 73984-73994.	0.8	23
58	Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. <i>BMC Cancer</i> , 2015, 15, 700.	1.1	37
59	Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2015, 51, 742-750.	1.3	86
60	Comparison of Response Evaluation Criteria in Solid Tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: A retrospective analysis. <i>European Journal of Cancer</i> , 2015, 51, 202-209.	1.3	25
61	Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study. <i>BJU International</i> , 2015, 115, 65-73.	1.3	9
62	CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 949-956.	5.1	298
63	Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 531-540.	5.1	56
64	Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 457-464.	5.1	93
65	Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2797-2802.	0.8	153
66	Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). <i>Annals of Oncology</i> , 2015, 26, 2168-2173.	0.6	93
67	The off-label use of targeted therapies in sarcomas: the OUTCâ€™S program. <i>BMC Cancer</i> , 2014, 14, 870.	1.1	20
68	Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial. <i>Annals of Oncology</i> , 2014, 25, 1762-1769.	0.6	65
69	Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. <i>Targeted Oncology</i> , 2014, 9, 273-277.	1.7	23
70	Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. <i>Annals of Oncology</i> , 2014, 25, 730-734.	0.6	91
71	Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. <i>Annals of Oncology</i> , 2014, 25, 735-742.	0.6	149
72	Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group. <i>BMC Cancer</i> , 2014, 14, 156.	1.1	32

#	ARTICLE	IF	CITATIONS
73	ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS).. Journal of Clinical Oncology, 2014, 32, 10501-10501.	0.8	8
74	Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02. Radiation Oncology, 2013, 8, 40.	1.2	6
75	Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer, 2013, 13, 64.	1.1	66
76	Advanced chondrosarcomas: role of chemotherapy and survival. Annals of Oncology, 2013, 24, 2916-2922.	0.6	184
77	Sorafenib in patients with progressive epithelioid hemangioendothelioma. Cancer, 2013, 119, 2639-2644.	2.0	97
78	Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Investigational New Drugs, 2013, 31, 1626-1627.	1.2	52
79	Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy. Journal of Clinical Oncology, 2013, 31, 2485-2492.	0.8	213
80	Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. Annals of Oncology, 2013, 24, 2681-2685.	0.6	19
81	Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE. Annals of Oncology, 2013, 24, 824-831.	0.6	45
82	A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCCYN study). A study of the French Sarcoma Group. Annals of Oncology, 2013, 24, 1099-1104.	0.6	114
83	Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Annals of Oncology, 2012, 23, 2153-2161.	0.6	66
84	Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Annals of Oncology, 2012, 23, 517-523.	0.6	91
85	Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist, 2012, 17, 260-266.	1.9	170
86	Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist, 2012, 17, 1213-1220.	1.9	182
87	Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Annals of Oncology, 2012, 23, 1601-1607.	0.6	117
88	Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. Clinical Cancer Research, 2012, 18, 4458-4464.	3.2	194
89	Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Annals of Oncology, 2012, 23, 182-186.	0.6	130
90	Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. Annals of Surgical Oncology, 2012, 19, 1551-1559.	0.7	57

#	ARTICLE	IF	CITATIONS
91	Transcription Factor E3 and Transcription Factor EB Renal Cell Carcinomas: Clinical Features, Biological Behavior and Prognostic Factors. <i>Journal of Urology</i> , 2011, 185, 24-29.	0.2	91
92	Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. <i>Annals of Oncology</i> , 2010, 21, 1834-1838.	0.6	188
93	Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: CORTEC 2006-01. <i>Journal of Clinical Oncology</i> , 2010, 28, 21-28.	0.8	172
94	Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 1361-1365.	0.6	38
95	Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. <i>Annals of Oncology</i> , 2009, 20, 425-430.	0.6	129
96	Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2009, 55, 1368-1376.	0.9	118
97	Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 5269-5274.	0.8	569
98	Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 1107-1113.	0.8	359